Real World Evidence Studies: Market Size & Forecast 2026

The global Real World Evidence Studies market sits at approximately USD 2.8 billion in 2025 (base year), expanding at a 12.5% CAGR to reach roughly USD 6.4 billion by 2032. The category occupies a structurally tight position: regulatory acceptance of RWE in drug and device submissions has materially accelerated over the past 24 months, while the underlying cost of patient-level longitudinal health records, the primary feedstock, has risen sharply, particularly in the United States where industry benchmarks now place US patient-year pricing at roughly USD 850 against a global range of USD 380-850 depending on data richness and geography. EV-specific coolant grows at roughly 10 percent off a low base; the volume contribution to 2032 total demand is approximately 3 percent, which is why the headline displacement thesis is overstated even though the formulation-spec premium is real. > **Anal

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.